Company News
Pharmaceutical company announces intent to leverage PADnet for FDA Phase III Trial
AngioSoma (OTC: SOAN) recently announced their intent to work with Biomedix to use PADnet for clinical research and trials, to evaluate the efficacy of their pharmaceutical intervention for PAD. AngioSoma intends to use the PADnet device to select patients for clinical trials and determine the presence and severity of PAD Read more…
